Azitra, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Azitra, Inc. (AZTR) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $0.27 per share as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2026-02-27
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $0.27.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $0.70.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $0.26.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $0.30.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price as first filed |
|---|---|---|
| 2025-12-31 | $0.27 10-K · filed 2026-02-27 | |
| 2025-09-30 | $0.70 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.26 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $0.30 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $0.43 10-K · filed 2026-02-27 | |
| 2024-09-30 | $0.54 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.76 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $0.26 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $27.60 10-K · filed 2025-02-24 | $0.92 10-K · filed 2024-03-15 |
| 2023-09-30 | $1.50 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $1.70 10-K · filed 2024-03-15 | $12.09 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |